Author:
Mehta Lovekesh,Naved Tanveer,Grover Parul,Bhardwaj Monika,Mukherjee Debaraj
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference14 articles.
1. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia;Chavez;Core Evid.,2013
2. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy;Honigberg;Proc. Natl. Acad. Sci.,2010
3. Ibrutinib: implications for use in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia;McNally;J. Adv. Pract. Oncol.,2015
4. Disruption of in vivo chronic lymphocytic leukemia tumor–microenvironment interactions by ibrutinib–findings from an investigator-initiated phase II study;Niemann;Clin. Cancer Res.,2016
5. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL;Herman;Blood J. Am. Soc. Hematol.,2014
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献